Rituximab + Pembrolizumab
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Marginal Zone Lymphoma
Conditions
Marginal Zone Lymphoma
Trial Timeline
Mar 1, 2022 → Dec 6, 2024
NCT ID
NCT04268277About Rituximab + Pembrolizumab
Rituximab + Pembrolizumab is a phase 2 stage product being developed by Celltrion for Marginal Zone Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04268277. Target conditions include Marginal Zone Lymphoma.
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04268277 | Phase 2 | Terminated |
Competing Products
10 competing products in Marginal Zone Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Copanlisib + Rituximab | Celltrion | Phase 2 | 39 |
| Pirtobrutinib + Rituximab | Eli Lilly | Phase 2 | 42 |
| Epcoritamab | AbbVie | Phase 2 | 42 |
| Rituximab + Venetoclax | AbbVie | Phase 2 | 39 |
| VAY736 + lenalidomide | Novartis | Phase 1 | 21 |
| PI3K inhibitor BKM120 + rituximab | Novartis | Phase 1 | 29 |
| Obinutuzumab | Roche | Phase 2 | 39 |
| Umbralisib | TG Therapeutics | Phase 2 | 32 |
| HMPL-689 | HUTCHMED | Phase 2 | 29 |
| Loncastuximab tesirine 150 µg/Kg + Loncastuximab tesirine 75µg/Kg | ADC Therapeutics | Phase 2 | 36 |